Postoperative abdominal endogenic field hyperthermia combined with FOLFOX regimen in the treatment of 68 cases of advanced gastric cancer.
- Author:
Xian-Gan LIN
1
;
Kai-Hong HUANG
;
De-Rong XIE
;
Tian-Hao LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Combined Modality Therapy; Female; Fluorouracil; therapeutic use; Humans; Hyperthermia, Induced; Leucovorin; therapeutic use; Male; Middle Aged; Organoplatinum Compounds; therapeutic use; Stomach Neoplasms; drug therapy; pathology; surgery; therapy; Treatment Outcome
- From: Journal of Southern Medical University 2007;27(10):1501-1503
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the therapeutic efficacy and adverse effects of endogenetic field hyperthermia (EFH) in combination with L-OHP /LV / 5-FU in the treatment of advanced gastric cancer.
METHODSThis study included 147 surgical patients with stage II-IV gastric cancer, who received postoperative chemotherapy with FOLFOX (L-OHP 85 mg /m square, 3 h intravenous infusion, followed by infusion of LV at 200 mg /m square in 2 h, intravenous injection of 5-Fu at 400 mg /m square, and intravenous infusion of 5-FU at 3000 mg /m square in 48 h). Eight treatment cycles (each lasting for 14 days) were administered. In 68 cases randomly selected from the cohort, EFH was performed on the first and third days (treatment group), but not in the other 79 cases (control group).
RESULTSThe response rate was 68.4% in the treatment group and 36.4% in the control group, showing significant difference between them (P<0.05). The 1-year survival rate was 88.2% in the treatment group, similar to the rate of 81.0% in the control group (P< 0.05), but the 3, 5-year survival rates in treatment group (67.6% and 30.9%) was significantly higher than those in the control group (47.6% and 15.4%, P<0.05). The adverse effects were similar between the two groups.
CONCLUSIONEFH combined with the chemotherapeutic regimen FOLFOX might improve the therapeutic effect of stage II-IV gastric cancer without obviously increasing the adverse effects.
